BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Protagen AG Closes New Round of Financing to Strengthen Technology Position for Novel Diagnostics


8/1/2008 7:58:12 AM

Dortmund, Germany and New Jersey, USA, August 1, 2008: Protagen AG, a leading provider of GMP compliant protein analytical services, protein bio­informatics, and protein biochips announces the closing of a new round of financing. The capital will be used to strengthen and expand the company’s UNIarray® technology position and the development of novel diagnostics. The capital raised in this round has come from the existing institutional investors, MIG AG, Munich, S-Venture Capital Dortmund GmbH, and Kreditanstalt für Wiederaufbau (KfW).

Background: UNIarray® is a unique technology platform for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals. Therefore, the systematic and indication-specific determination of autoanti­body patterns will serve as a unique basis to address hitherto unmet dia­gnostic needs. In addition, UNIarray® serves as a platform for the develop­ment of product specific companion diagnostics and patient stratification for clinical studies. In-house research at Protagen is presently focused on novel diagnostics for prostate cancer, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, Morbus Parkinson, and Alzheimer’s.

At the same time Dr. Christoph Hüls (CEO) will leave Protagen for private reasons and will move to a new position in a large pharmaceutical company. The Chairman of the Board of Protagen AG, Prof. Axel Kleemann, regrets the departure of Christoph Hüls and the end of a long and trustful cooperation. Dr. Stefan Müllner (CSO) will take over the position as new CEO.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES